Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Relapsed/refractory B-Cell non-Hodgkin lymphoma, Relapsed/refractory multiple myeloma
Conditions
Brief summary
The type and incidence of targeted adverse events (AEs), The type and incidence of serious AEs (SAEs) considered related to the GLPG CAR T-cell therapy, The pattern of vector integration sites, if vector sequences are detected in new malignancies, or in at least 1% of peripheral blood mononuclear cells (PBMCs), The incidence of detectable replication-competent lentivirus (RCL) in peripheral blood, Cause-specific mortality
Detailed description
Disease progression status, Time to subsequent anticancer therapy, Overall survival, The incidence of detectable CAR transgene in peripheral blood over time
Sponsors
Galapagos Cell Therapeutics
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The type and incidence of targeted adverse events (AEs), The type and incidence of serious AEs (SAEs) considered related to the GLPG CAR T-cell therapy, The pattern of vector integration sites, if vector sequences are detected in new malignancies, or in at least 1% of peripheral blood mononuclear cells (PBMCs), The incidence of detectable replication-competent lentivirus (RCL) in peripheral blood, Cause-specific mortality | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease progression status, Time to subsequent anticancer therapy, Overall survival, The incidence of detectable CAR transgene in peripheral blood over time | — |
Countries
Belgium, Netherlands, Spain
Outcome results
None listed